Mansor S M, Taylor T E, McGrath C S, Edwards G, Ward S A, Wirima J J, Molyneux M E
Department of Pharmacology and Therapeutics, University of Liverpool, UK.
Trans R Soc Trop Med Hyg. 1990 Jul-Aug;84(4):482-7. doi: 10.1016/0035-9203(90)90007-2.
The safety and kinetics of intramuscular quinine (10 mg salt/kg every 8 h for 3 doses) were assessed in Malawian children suffering from uncomplicated falciparum malaria, who were unable to take oral antimalarial drugs. Treatment was completed with oral pyrimethamine-sulfadoxine. The mean (+/- SD) peak plasma quinine concentration after the first injection was 9.0 (+/- 2.3) micrograms/ml, at 1.1 (+/- 0.7) h. Mean plasma concentrations increased further after the second and third doses to a maximum of 11.5 (+/- 2.6) micrograms/ml at 16.1 (+/- 3.2) h. No hypotension, hypoglycaemia or electrocardiographic abnormalities developed during quinine treatment. These results provide further evidence for the safety of intramuscular quinine in children with moderately severe malaria. Plasma concentrations of alpha 1-acid glycoprotein (AGP) were higher, and the degree of protein binding of quinine was greater, in acute malaria than in convalescence. There was a significant correlation between AGP concentration and the fraction of plasma quinine bound to plasma protein. These findings suggest a role for AGP in the binding of quinine in plasma in vivo and are of interest since unbound quinine is responsible for both the efficacy and toxicity of the drug.
在无法口服抗疟药物的马拉维患单纯性恶性疟的儿童中,评估了肌肉注射奎宁(每8小时10毫克盐/千克,共3剂)的安全性和动力学。治疗最后使用口服乙胺嘧啶 - 磺胺多辛完成。首次注射后,平均(±标准差)血浆奎宁峰值浓度在1.1(±0.7)小时时为9.0(±2.3)微克/毫升。第二次和第三次给药后,血浆平均浓度进一步升高,在16.1(±3.2)小时时最高达到11.5(±2.6)微克/毫升。奎宁治疗期间未出现低血压、低血糖或心电图异常。这些结果为肌肉注射奎宁在中度重症疟疾儿童中的安全性提供了进一步证据。与恢复期相比,急性疟疾时α1 - 酸性糖蛋白(AGP)的血浆浓度更高,奎宁的蛋白结合程度也更高。AGP浓度与血浆中与血浆蛋白结合的奎宁部分之间存在显著相关性。这些发现表明AGP在体内血浆中奎宁的结合中起作用,并且由于游离奎宁是药物疗效和毒性的原因,因此具有重要意义。